NBI-1117568
Phase 3Recruiting 0 watching 0 views this week📈 Rising
74
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Schizophrenia
Conditions
Schizophrenia
Trial Timeline
Jul 11, 2025 → Dec 1, 2031
NCT ID
NCT07114874About NBI-1117568
NBI-1117568 is a phase 3 stage product being developed by Neurocrine Biosciences for Schizophrenia. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07114874. Target conditions include Schizophrenia.
Hype Score Breakdown
Clinical
27
Activity
18
Company
7
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07114874 | Phase 3 | Recruiting |
Competing Products
20 competing products in Schizophrenia